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FoxM1 is a member of the forkhead family of transcription factors. Since its
identification 15 year ago, numerous studies have progressively contributed to our
current understanding on FoxM1 functions. Early work showed that FoxM1 regulates
the transcriptional program of the G2 phase of the cell cycle, and is essential for
proper mitotic progression and genomic stability. Moreover, FoxM1 was found to be
overexpressed in many different types of human cancer, suggesting a role of FoxM1
in tumor proliferation. In the past years, a significant number of studies have formally
demonstrated the involvement of FoxM1 in different aspects of tumorogenesis, including
angiogenesis, invasion, and metastasis. In addition to this, recent studies have placed
FoxM1 in DNA damage response and senescence pathways, two pathways relevant to
tumor progression and the response to cancer therapies. Here, we review and discuss
the molecular mechanisms through which FoxM1 executes these new roles, and the
implications for the potential use of FoxM1 as a therapeutic target in cancer.
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INTRODUCTION
FoxM1, also known as Trident, MPP2, or HFH-11, belongs to
the large family of forkhead transcription factors (Korver et al.,
1997b). Forkhead box (Fox) proteins are a superfamily of evolu-
tionarily conserved transcriptional regulators, defined by a com-
mon DNA binding domain termed the forkhead box or winged
helix domain (Myatt and Lam, 2007). FoxM1 binds promoter
regions with a preference for a consensus “TAAACA” recogni-
tion sequence, although with lower affinity than other forkhead
proteins (Littler et al., 2010). Its expression is restricted to prolif-
erating cells, and excluded from quiescent and terminally differ-
entiated cells (Korver et al., 1997a; Ye et al., 1997). Its expression,
both at the mRNA and protein levels, is cell cycle-regulated: it
increases at the entry of S-phase, peaks during G2 and M, and is
degraded during mitotic exit (Laoukili et al., 2008b; Park et al.,
2008). Similarly, its transcriptional activity is tightly regulated
throughout the cell cycle by multisite phosphorylation by differ-
ent kinases (Fu et al., 2008; Laoukili et al., 2008a; Anders et al.,
2011), and its counteracting phosphatases (Alvarez-Fernandez
et al., 2011), reaching its maximum activity in the G2 phase of
the cell cycle. FoxM1 is a critical cell cycle regulator. It controls
the expression of genes required for both G1/S and G2/M tran-
sition (Laoukili et al., 2005; Wang et al., 2005); and it is essential
for mitotic entry and progression, ensuring the maintenance of
chromosome stability (Laoukili et al., 2005).
Amplifications of the 12p13 chromosomal band, compris-
ing the FoxM1 gene, have been reported in numerous tumors
such as cervical squamous cell carcinomas, breast adenocarcino-
mas, nasopharyngeal carcinomas, and head and neck squamous
cell carcinomas (Singh et al., 2001). FoxM1 is one of the most
common genes overexpressed in solid tumors of prostate, lung,
bladder, ovary, colon, liver, breast, kidney, stomach, and pan-
creas (Pilarsky et al., 2004). It is also aberrantly expressed in other
cancers, such as basal cell carcinomas (Teh et al., 2002), glioblas-
tomas (Liu et al., 2006), or acute myeloid leukemia (Nakamura
et al., 2010). Recently, it has been reported that FoxM1 expression
can also be modulated by microRNAs. FoxM1 has been iden-
tified as a direct target of miR-134, whose levels are inversely
correlated with the invasive potential of some NSCLC cells (Li
et al., 2012). Moreover, FoxM1 is also repressed by miR-370, a
tumor suppressor miRNA frequently silenced in acute myeloid
leukemia (Zhang et al., 2012b). In addition to its positive role
on cell proliferation, FoxM1 has been shown to play roles in
other cancer-related processes, such as invasion and metastasis
(Dai et al., 2007; Wang et al., 2008; Park et al., 2011; Huang
et al., 2012). Moreover, its expression levels correlate with poor
prognosis and metastasis in different tumors, suggesting the pos-
sibility of using FoxM1 as a prognosis and/or diagnosis marker
[revised in (Teh, 2012)]. In the past years, it has also become clear
that FoxM1 plays important roles in the DNA damage response
and senescence pathways. Early tumor lesions show DNA dam-
age and senescence markers, probably due to oncogene activation
and unscheduled proliferation. Importantly, oncogene-induced
replicative stress and senescence are tumor barriers that tumor
cells need to bypass to allow cancer progression. Moreover, most
commonly used cancer treatments rely on the induction of DNA
damage, leading to apoptosis, and eventually senescence response,
in order to prevent tumor cell expansion (Nardella et al., 2011;
Lord and Ashworth, 2012). Therefore, it is critical to under-
stand the specific roles that FoxM1 plays in these pathways in
order to design better therapeutic approaches. Here, we sum-
marize those findings on FoxM1 function in DNA damage and
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FIGURE 1 | FoxM1 functions in response to DNA damage and
oxidative stress. FoxM1 regulates the response to DNA damage at
different levels. Upon genotoxic treatments, FoxM1 is required for
efficient DNA repair and cell cycle resumption once the damage is
repaired. Moreover, FoxM1 prevents DNA damage-induced apoptosis, and
protect cells from oxidative stress-induced senescence. These FoxM1
functions favor tumor growth, and open different possibilities of targeting
FoxM1 in cancer therapies.
senescence processes, and its impact on therapeutic strategies
against cancer.
FoxM1 AND THE DNA DAMAGE RESPONSE
The first evidence of the implication of FoxM1 in DNA dam-
age pathways came from the observation that FoxM1-deficient
cells showed increased levels of DNA damage. Mouse embryonic
fibroblasts (MEFs) derived from FoxM1 knockout mouse dis-
played high levels of the γH2AX marker compared to wild-type
MEFs (Tan et al., 2007). Those cells also showed an increased
number of TUNEL foci, which efficiently end label sites of DNA
breaks, suggesting a defect in DNA repair (Tan et al., 2007).
High levels of spontaneous γH2AX foci were also detected in
osteosarcoma U2OS cells depleted of FoxM1 by RNA inter-
ference, and correlated with decreased levels of X-ray repair
cross-complementing protein 1 (XRCC1) and breast cancer–
associated gene 2 (BRCA2), two genes involved in DNA repair
(Tan et al., 2007). Although both genes were proposed as FoxM1
targets, they have not been proven to be the mediators of such
increase in spontaneous damage observed in FoxM1-deficient
MEFs (Tan et al., 2007). Indeed, knockdown of FoxM1 in breast
cancer cells also led to an increase in DNA damage, but did not
result in the downregulation of those potential FoxM1 targets,
BRCA2, and XRCC1, neither at protein nor mRNA level (Kwok
et al., 2010). These results suggest that FoxM1 might regulate
the expression of other genes involved in DNA damage repair
pathways.
Interestingly, a recent report has shown that FoxM1 null
MEFs are hypersensitive to different DNA damaging insults, such
as epirubicin (a topoisomerase II inhibitor), or γ-irradiation
(IR), suggesting again a role of FoxM1 in DNA damage repair
(Monteiro et al., 2012). In the same study, it was demon-
strated for the first time that FoxM1 is required for DNA
double strand break (DSB) repair by homologous recombi-
nation (HR) but dispensable for non-homologous end-joining
(NHEJ) repair (Monteiro et al., 2012). In agreement with that,
BRIP (BRCA1-associated BACH1 helicase), a protein involved
in HR DSB repair, was identified as a direct transcriptional
target of FoxM1. Importantly, ectopic BRIP expression can par-
tially rescue the increased damage and repair deficiency of
FoxM1 null cells (Monteiro et al., 2012). This indicates that
FoxM1 mediates HR repair at least in part through transcrip-
tional regulation of BRIP, although other targets are likely to
be involved in this function of FoxM1. For instance, Rad51,
another critical protein required for efficientHR repair, contains 2
forkhead-binding sites in its promoter, and has also been
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described as a transcriptional target of FoxM1 in glioblastoma
cells (Zhang et al., 2012a).
FoxM1 has been reported to modulate drug sensitivity and
resistance in various tumor types. In breast cancer cell lines with
acquired resistance for cisplatin or epirubicin FoxM1 was found
to be overexpressed and its depletion was able to re-sensitize these
cell lines to the respective genotoxic drug (Kwok et al., 2010;
Monteiro et al., 2012). Silencing of FoxM1 also led to higher sen-
sitivity to doxorubicin in breast cancer cells in a xenograft mouse
model (Park et al., 2012). FoxM1 has also been linked to geno-
toxic drug resistance in glioblastoma multiforme (GBM). FoxM1
was found significantly upregulated in recurrent GBM tumor
samples compared with primary tumors, and its expression lev-
els correlated with poor response to the alkylator temolozide. In
both tumor types, FoxM1-dependent chemotherapy resistance
was partially mediated by enhanced expression of DNA repair
genes, BRIP, and Rad51, respectively, although it is likely that
other FoxM1 targets with repair roles are also involved (Monteiro
et al., 2012; Zhang et al., 2012a). Besides DNA repair, it is also
possible that other FoxM1 functions contribute to chemotherapy
resistance. For instance, FoxM1 is critical for checkpoint recovery
upon doxorubicin or IR treatment. Following a DNA damage-
induced G2 arrest, FoxM1 transcriptional activity is required to
maintain the expression of pro-mitotic genes, such as cyclins
or Plk1, in order to allow re-entry into the cell cycle, once the
damage is repaired (Alvarez-Fernandez et al., 2010). Moreover,
a recent study has proposed that FoxM1 may inhibit DNA-
damage-induced apoptosis by upregulating the proapototic Bcl-2,
although it has not been confirmed to be a direct FoxM1 tran-
scriptional target (Halasi and Gartel, 2012a). These data suggest
that FoxM1 might induce genotoxic resistance at different lev-
els, through the enhancement of DNA damage repair, by favoring
recovery after damage and preventing apoptosis (Figure 1).
Not only does FoxM1 control the DNA damage response,
FoxM1 itself is also regulated in response to DNA damage.
Stabilization of FoxM1 upon damage has been reported in sev-
eral cell lines upon different DNA damaging insults, mostly at
the protein level (Tan et al., 2007; Teh et al., 2010). Treatment
with different DNA damaging agents, such as IR, etoposide, or
UV, were reported to induce FoxM1 phosphorylation by Chk2
and stabilization at the protein level (Tan et al., 2007). On the
contrary, other studies have shown that FoxM1 is repressed by
p53 in response to damage (Barsotti and Prives, 2009; Pandit
et al., 2009), while in other cases, no effect on FoxM1 expression
was detected in response to damaging insults (Alvarez-Fernandez
et al., 2010; Halasi and Gartel, 2012a). Therefore, it seems that
FoxM1 regulation by the DNA damage response varies depending
on the cellular context and, as such, the mechanisms controlling
such regulation require further investigation.
FoxM1 AND SENESCENCE
In addition to the increase in DNA damage, MEFs derived from
FoxM1 knockout mice also showed premature senescence (Wang
et al., 2005). Consistent with this, FoxM1 was reported to be
one of the most significantly downregulated transcription fac-
tors in human fibroblasts undergoing senescence upon activation
of the p16-Rb and p53-21 pathways, and overexpression of its
constitutive active form was sufficient to bypass senescence in this
system (Rovillain et al., 2011). In agreement with this, FoxM1
overexpression was able to prevent oxidative stress-induced senes-
cence in mouse fibroblasts (3T3), and this correlated with the
induction of the Polycomb group protein Bmi-1, a major nega-
tive regulator of the Ink4a/Arf/Ink4b locus that encodes p19Arf
as well as the cyclin-dependent kinase inhibitors p16 and p15 (Li
et al., 2008). However, it has not been demonstrated that Bmi-1 is
the transcriptional target of FoxM1 mediating this effect.
In a more recent study, human primary fibroblasts (IMR90)
depleted of FoxM1 also exhibited a senescence-like phenotype
and were more sensitive to H2O2-induced senescence, indicating
again that FoxM1 could protect cells from oxidative stress (Park
et al., 2009). From the molecular point of view, the same study
demonstrated that FoxM1 regulates intracellular levels of ROS
through transcriptional induction of anti-oxidant genes, such as
catalase and MnSOD (Park et al., 2009). These previous find-
ings of FoxM1 exhibiting senescence-suppressing activity were
confirmed in a recent study using FoxM1 null MEFs challenged
with the ROS inducing drug Imexon (Anders et al., 2011). In
this work, FoxM1 was also identified as a critical substrate of
CDK4/6 kinases that mediates senescence suppression in cancer
cells through ROS regulation and the activation of genes required
for the G1/S transcription (Anders et al., 2011) (Figure 1).
THERAPEUTIC OPPORTUNITIES OF TARGETING FoxM1
During the last years, significant progress has beenmade in target-
ing FoxM1 in cancer [for a recent review see (Halasi and Gartel,
2012b)]. The above described functions of FoxM1 in DNA dam-
age response and senescence pathways open new scenarios in
which targeting FoxM1might be of clinical benefit. Its role in DSB
HR repair makes it an attractive target for combination therapies
with treatments that render cells dependent on that DNA repair
mechanism. That is the case for DSBs inducing agents, such as
topoisomerase inhibitors, IR, or alkylators. Indeed, recent stud-
ies have already shown that targeting FoxM1 sensitizes different
tumor cells to those DNAdamaging treatments (Kwok et al., 2010;
Halasi and Gartel, 2012a; Zhang et al., 2012a). Another interest-
ing strategy is the possibility of combining FoxM1 inhibition with
PARP inhibitors. PARP polymerases are required to repair single
strandDNAbreaks occurring during replication.When inhibited,
unrepaired single-stranded DNA breaks result in stalled repli-
cation forks, which must be repaired by HR. Inhibiting HR, by
means of FoxM1 suppression, may therefore sensitize these cells
to PARP inhibitors.
The senescence suppression role of FoxM1 also offers possi-
bilities of therapeutic intervention. That is the case of malignant
melanoma, which is characterized for its chemoresistance. A
recent study, already mentioned above, showed that treatment
with CDK4/6 inhibitors, which inhibits FoxM1, triggered a strong
senescence response in all melanoma cell lines tested but not
in primary melanocytes (Anders et al., 2011). This provides an
excellent therapeutic window for targeting Cdk4/6-FoxM1 sig-
naling in order to reactivate a senescence program in cancer
cells. Moreover, it is now becoming apparent that most conven-
tional chemotherapies, which aim to induce extensive damage
and apoptotic responses, are accompanied by a robust and
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concomitant induction of senescence (te Poele et al., 2002).
Interestingly, it is also now evident that senescent cells can
be cleared in vivo through the innate immune response (Xue
et al., 2007). Therefore, combination of chemotherapy or IR
with FoxM1 inhibition might improve the efficacy of those can-
cer treatments. Moreover, depending on the type of DNA lesion
induced, FoxM1 inhibition might work at multiple levels, by
blocking both DNA repair and checkpoint recovery processes,
and promoting senescence.
One of the current limitations of targeting FoxM1 in cancer
is its “druggability,” being a transcription factor. In the past years
different compounds have been identified as FoxM1 inhibitors,
such as the thiazole antibiotics Syomicin A (Radhakrishnan et al.,
2006) and Thiostrepton (Bhat et al., 2009b). Surprisingly, these
inhibitors do not affect the transcriptional activity of FoxM1
per se, but inhibit its expression at both mRNA and protein levels
through an unknown mechanism (Bhat et al., 2009a). Other gen-
eral proteasome inhibitors, such as bortezomib or MG132, also
affected FoxM1 at the same level (Bhat et al., 2009a). In addi-
tion to this, the Balasubramanian group provided an alternative
mode of action for Thiostrepton (Hegde et al., 2011). They
showed that thiostrepton directly binds FoxM1, blocking its
binding to the promoters of its target genes. Obviously, fur-
ther studies will be required to elucidate the precise mechanism
of action of these compounds, and this will hopefully help to
develop more selective and specific FoxM1 inhibitors for cancer
treatment.
CLOSING REMARKS
FoxM1 is a promising and attractive target for cancer therapy.
Significant progress has been made in the past years on FoxM1
function in DNA damage and senescence pathways, as well as
in the possibilities of targeting FoxM1 in cancer. However, more
studies are needed to further understand the precise mechanisms
and transcriptional targets involved in those functions, in differ-
ent cellular contexts and tumor types, and in response to different
types of damage. This, together with the development of more
specific inhibitors, will definitely help to define the proper ther-
apeutic window in which targeting FoxM1 can achieve clinical
benefits.
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